CS-3000 plus血细胞分离机在治疗性血液成分单采中的临床应用

【目的】观察应用CS-3000plus血细胞分离机进行治疗性血液成分单采的临床疗效，分析影响血液成分单采效果的相关因素。【方法】对87例患者应用CS-3000plus血细胞分离机进行161次治疗性血液成分单采，分析临床效果和实验室指标的改善情况。【结果】应用CS-3000plus血细胞分离机进行血浆置换后，71．43％患者临床症状、体征或者实验室指标取得明显改善。相关分析提示，进行治疗性血细胞成分单采患者的白细胞、血小板、红细胞、血红蛋白、红细胞比容下降值与采前相应初始值均呈正相关（P〈0．05）。白细胞单采术的患者白细胞计数下降值与处理全血量呈正相关（P〈0．05），在处理血量达到5000～7000ml时，血小板单采术患者血小板计数下降值与处理全血量无明显相关性（P〉0．05）。当处理全血量达到500～800ml时，红细胞单采术患者红细胞、血红蛋白、红细胞比容下降值与处理全血量无明显相关性（P〉0．05）。【结论】应用CS-3000plus血细胞分离机进行治疗性血液成分单采对迅速缓解临床症状，减少并发症的发生和提高临床药物治疗效果均有较大意义。合理设定全血处理量，调整采集相关参数，有助于采集的顺利进行和采集效果的进一步提高。     

Hemapheresis in pregnancy.

Plasma exchange in pregnancy has benefited those diseases that occur and are treated in the nonpregnant patient. In addition, special emphasis was given to diseases unique to pregnancy, such as hemolytic disease of the newborn, which is significantly modified by plasma exchange therapy. Fluid volumes, replacement solution, and techniques were discussed.     

血液成分单采术在血液病中的应用及不良反应的观察

目的 初步探讨血液成分单采术在血液病治疗中的应用并观察其不良反应.方法 对524例患者应用CS-3000 plus血细胞分离机进行916次治疗性血液成分单采,根据病人情况选择不同细胞收集程序,分析临床效果和实验室指标的改善情况,并分析其不良反应及处理措施.结果 行血细胞单采术后210例高白细胞患者白细胞由(230.1±48.5)×109/L降至(49.3±10.0)×109/L;123例真性红细胞患者血红蛋向由(216.0±23.0)g/L降至(150.0±12.0)g/L,红细胞由(7.1±0.5)×1012/L降至(4.3±O.8)×1012/L;158例高血小板患者血小板由(1 080.0±314.0)×109/L降至(341.0±82.0)×109/L,治疗前后差异均有统计学意义(P<0.01).32例血栓性血小板减少性紫癜患者行血浆置换后,90.6%患者临床症状、体征及实验室指标均明显改善.少部分患者出现枸橼酸盐中毒(3.0%)、低血容量休克(0.7%)、过敏反应(4.6%)等不良反应,经对症处理后均得以缓解.结论 利用血细胞分离机进行治疗性血液成分单采术和血浆置换术可迅速缓解临床症状,减少并发症的发生,疗效肯定且安全可靠,不良反应少,并对提高临床药物治疗效果有很大意义.     

American Society for Apheresis,Society of Hemapheresis Specialists and Francis S. Morrison,MD, revisited

The histories of the American Society for Apheresis (ASFA) and the Society for Hemapheresis Specialists (SHS) are intimately intertwined with Francis S Morrison, MD. Because many of the relevant historical events are not recorded as written documents, it is useful to revisit them via the memory of those who lived‐through the growth and development of ASFA. ASFA began in 1982 as an organization of physicians interested in automated hemapheresis—actually, meetings of ASFA perse were preceded in the late 1970s by apheresis symposia sponsored by the American Red Cross Blood Services in Chicago. Concurrently, SHS formed as an organization of nurses and “operators” performing hemapheresis procedures and held meetings separate from ASFA. Following a number of turbulent years, ASFA and SHS merged. Trusting my memory and a few personal documents, I will touch on many of the notable events of ASFA and SHS history. Because of the leadership of Dr. Fran Morrison during many crucial events in ASFA history, I will make special efforts to remember his contributions to ASFA as an organization and the ways in which he touched the lives of many ASFA members. J. Clin. Apheresis., 2007 © 2007 Wiley‐Liss, Inc.